Furthermore, LOXL2, as a copper-dependent enzyme, could be inhibited by copper chelation agents, such as penicillamine, trientine, disulfiram, clioquinol, or tetrathiomolybdate (TM), which could be used in cancer treatment (45, 46). Here, LOXL2 is linked to cancer.